Glimgold MV 2mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 2mg, Metformin 500mg, and Voglibose 0.2mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, minimizing postprandial hyperglycemia. This triple combination targets multiple pathophysiological defects in type 2 diabetes, offering comprehensive glycemic management. Glimgold MV 2mg Tablet is prescribed as an adjunct to diet and exercise when monotherapy or dual therapy is insufficient. It is essential to monitor blood glucose levels regularly and assess renal and hepatic function prior to and during therapy to minimize adverse effects such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances. Dose adjustments may be necessary based on therapeutic response and tolerability. Patient education on adherence, lifestyle modifications, and recognition of hypoglycemia symptoms is crucial for optimal outcomes. This medication should be used under strict medical supervision.